Arvinas, Inc. (ARVN)
Nasdaq · Healthcare · Biotechnology
$7.46+0.67%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $481M
- P/E (trailing)
- 28.7
- 52-week range
- $6.97 – $14.51
- 52-week change
- −20.32%
- EPS (trailing)
- $0.26
- Analyst rating
- 2.4 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $263M (−0.30%)
- Net income
- −$81.0M
- Operating margin
- −45.1%
- Diluted EPS
- −$1.14
- Free cash flow
- −$276M
From the company’s annual report on SEC EDGAR.
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.
Headquarters: New Haven, United States · 246 employees · arvinas.com